I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| epithelial cell | 3 studies | 21% ± 3% | |
| hepatocyte | 3 studies | 45% ± 20% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| epithelial cell | 3 studies | 21% ± 3% | |
| hepatocyte | 3 studies | 45% ± 20% |
Insufficient scRNA-seq data for expression of MOCOS at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 2780.23 | 226 / 226 | 99% | 15.13 | 400 / 406 |
| bladder | 100% | 471.76 | 21 / 21 | 97% | 12.39 | 491 / 504 |
| breast | 100% | 845.08 | 458 / 459 | 96% | 11.75 | 1073 / 1118 |
| skin | 100% | 1073.86 | 1805 / 1809 | 88% | 13.88 | 415 / 472 |
| lung | 93% | 377.70 | 536 / 578 | 95% | 10.37 | 1092 / 1155 |
| esophagus | 83% | 526.09 | 1196 / 1445 | 98% | 13.97 | 179 / 183 |
| prostate | 99% | 464.11 | 242 / 245 | 81% | 3.24 | 405 / 502 |
| stomach | 79% | 221.51 | 284 / 359 | 98% | 9.80 | 279 / 286 |
| intestine | 73% | 377.82 | 704 / 966 | 98% | 10.05 | 515 / 527 |
| ovary | 100% | 1978.22 | 180 / 180 | 69% | 3.63 | 298 / 430 |
| pancreas | 63% | 134.77 | 207 / 328 | 93% | 6.61 | 166 / 178 |
| adrenal gland | 100% | 3127.99 | 258 / 258 | 50% | 7.55 | 114 / 230 |
| kidney | 92% | 330.12 | 82 / 89 | 51% | 3.70 | 464 / 901 |
| uterus | 47% | 122.65 | 80 / 170 | 91% | 16.63 | 417 / 459 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 14.70 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 7.13 | 1 / 1 |
| adipose | 96% | 619.75 | 1156 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 68% | 2.94 | 54 / 80 |
| blood vessel | 64% | 228.45 | 854 / 1335 | 0% | 0 | 0 / 0 |
| thymus | 29% | 50.32 | 188 / 653 | 30% | 1.28 | 184 / 605 |
| muscle | 28% | 81.56 | 225 / 803 | 0% | 0 | 0 / 0 |
| spleen | 25% | 56.18 | 61 / 241 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 21% | 1.47 | 6 / 29 |
| heart | 11% | 18.67 | 93 / 861 | 0% | 0 | 0 / 0 |
| brain | 3% | 6.14 | 89 / 2642 | 7% | 0.32 | 47 / 705 |
| peripheral blood | 7% | 21.60 | 69 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006777 | Biological process | Mo-molybdopterin cofactor biosynthetic process |
| GO_0032324 | Biological process | molybdopterin cofactor biosynthetic process |
| GO_0043545 | Biological process | molybdopterin cofactor metabolic process |
| GO_0005575 | Cellular component | cellular_component |
| GO_0005829 | Cellular component | cytosol |
| GO_0016829 | Molecular function | lyase activity |
| GO_0008265 | Molecular function | Mo-molybdopterin cofactor sulfurase activity |
| GO_0102867 | Molecular function | molybdenum cofactor sulfurtransferase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0030170 | Molecular function | pyridoxal phosphate binding |
| GO_0030151 | Molecular function | molybdenum ion binding |
| Gene name | MOCOS |
| Protein name | Molybdenum cofactor sulfurase (MCS) (MOS) (MoCo sulfurase) (hMCS) (EC 2.8.1.9) (Molybdenum cofactor sulfurtransferase) |
| Synonyms | |
| Description | FUNCTION: Sulfurates the molybdenum cofactor. Sulfation of molybdenum is essential for xanthine dehydrogenase (XDH) and aldehyde oxidase (ADO) enzymes in which molybdenum cofactor is liganded by 1 oxygen and 1 sulfur atom in active form. In vitro, the C-terminal domain is able to reduce N-hydroxylated prodrugs, such as benzamidoxime. . |
| Accessions | ENST00000261326.6 Q96EN8 |
